CA-SCIENTIST.COM
Scientist.com , the world's largest marketplace for outsourced research, announced today that it raised $24M in an equity financing co-led by Boston-based Leerink Transformation Partners (LTP) and San Francisco and Boston-based 5AM Ventures. Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo also participated. The funding will help the company expand its revolutionary pharmaceutical outsourcing marketplace.
The ongoing need and opportunity to improve pharmaceutical R&D efficiency is well documented. Last year marked a six-year low for new drug approvals; the industry spent $150 billion on R&D in 2016 but produced only 22 new medicines – well below the five-year average (2012-2016) of 29. The cost of bringing a single new drug to market has now reached as much as $7 billion, and profit margins have declined precipitously over the last 20 years.
“It is too expensive and time-consuming to bring new drugs to market,” said Jared Kesselheim, Managing Partner of LTP. “The outsourcing platform built by Scientist.com has enabled pharmaceutical companies to run drug programs in less time and at a fraction of today’s cost. We expect the marketplace to continue to be a game-changer for life science research, creating huge efficiencies for pharma companies and the entire scientific community.”
Scientist.com connects buyers and sellers of pharmaceutical research services, showcases the latest innovative tools and technologies and streamlines the entire ‘source-to-settle’ process. The company currently has multi-year partnerships with 12 of the top 25 large pharmaceutical companies and the US National Institutes of Health (NIH). Thousands of commercial suppliers (CROs) have already joined the Scientist.com network.
“We are fundamentally changing the way drug R&D is conducted,” said Kevin Lustig, PhD, President and CEO of Scientist.com. “Pharmaceutical company researchers can now outsource everything but the genius™, limited only by their imagination in the experiments they carry out. This investment will help us expand our seasoned team of industry experts and bring even more simplification and innovation to drug research.”
Scientist.com is extending the benefits of its platform to smaller, early-stage biopharmaceutical companies. An increasing number of biopharma start-ups are outsourcing many or all the laboratory tests, services and studies needed to run a complex, multi-year drug discovery and development program. A private marketplace located at app.scientist.com enables these virtual companies to run an entire drug program, from concept to clinic, using only their laptop computers and mobile phones.
“Scientist.com is pioneering a dramatically more efficient approach to drug research, enabling both large and small biopharmaceutical companies,” stated Paul Stone, 5AM Partner. “By solving the primary challenges currently facing the drug industry - how to effectively develop more medicines while reducing costs - the company has created a game-changing platform for all life science research.”
About Scientist.com
Scientist.com (formerly Assay Depot) is the world's largest scientific services marketplace. The marketplace simplifies research sourcing, saves time and money, and showcases innovative tools and technologies - while maintaining full compliance with an organization’s procurement policies. Scientist.com currently operates private marketplaces for 12 large pharmaceutical companies and the US National Institutes of Health (NIH). Other clients include hundreds of small pharmaceutical companies, government organizations, research universities, biotechnology companies, regional bioclusters and academic labs. Visit scientist.com to learn more.
About Leerink Transformation Partners (LTP)
LTP invests in privately-held innovative companies in the healthcare technology and services sectors. The firm was founded in 2015 by Todd Cozzens and Jared Kesselheim, M.D. Todd, most recently at Sequoia Capital, had a long operating career as CEO of Picis and as a senior executive at UnitedHealth Group/Optum. Jared, most recently at Bain Capital Ventures, was formerly a clinician at Massachusetts General Hospital. LTP applies its decades of operational and clinical experience and its extensive industry contacts to help founders and CEOs build important businesses. Founders today want more than just money and nowhere is this more apparent than in the complex, insular and dynamic healthcare market. Visit www.LTPequity.com to learn more.
About 5AM Ventures
Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. With ~$1 billion under management, 5AM has invested in over 60 companies and successful exits include DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (Nasdaq: RLYP, acquired by Galenica). Visit www.5amventures.com to learn more.
Join us on social media: Twitter , Facebook , Google+ and LinkedIn .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515005844/en/
Contact:
Scientist.com
Kevin Lustig
858-243-2227
kevin@scientist.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Launches Hyper 612 APEX: Compact, High-Performance CPU Cooler for Modern Builds12.5.2025 08:05:00 CEST | Press release
Advanced superconductive heat pipes and streamlined design deliver elite cooling power with greater system compatibility. Cooler Master, a global leader in PC components and tech lifestyle solutions, today unveiled the Hyper 612 APEX, an all-new CPU air cooler engineered for users who demand cutting-edge thermal performance in a streamlined footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511858017/en/ Cooler Master Hyper 612 APEX air cooler Featuring in-house developed superconductive composite heat pipes and the high-powered Mobius 120P fan, the Hyper 612 APEX delivers exceptional cooling efficiency while being 30% smaller than its predecessor, ensuring enhanced compatibility with large memory modules and tighter system builds. Ideal for gamers, content creators, and overclockers, the Hyper 612 APEX is meticulously designed to balance elite performance, user-friendly installation, and sleek aesthetics. “The Hyp
Zeon and Sino Applied Technology Join Hands to Expand Single-Walled Carbon Nanotube Conductive Paste Product Line and Promote the Application of Next-Generation Lithium Batteries in Electric Vehicles12.5.2025 08:00:00 CEST | Press release
Zeon Corporation (Zeon) and Sino Applied Technology (SiAT) are thrilled to announce the signing of a strategic partnership in Taoyuan, Taiwan. As part of this collaboration, Zeon will lead a $20 million USD Series C fundraising round in SiAT to support the expansion of its production capacity for single-walled carbon nanotube (SWCNT) conductive paste, a critical nanomaterial for next-generation battery technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511242604/en/ ZEONANO®, Single-Walled Carbon Nanotube produced by Zeon Super Growth Method The global demand for lithium-ion batteries is surging across consumer applications—such as electric vehicles, drones, and EVTOL aircraft—as well as industrial sectors, including AI server BBUs, renewable energy ESS, and automated robotics. This growth has intensified the need for SWCNTs, which can significantly enhance battery energy density and cycle life. Unlike tradition
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release
The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model
IFF Completes Divestiture of Nitrocellulose Business9.5.2025 14:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom